Current, Ongoing Phase III Trials of Napabucasin (BBI‑608)
Boston Biomedical featured 11 clinical data poster presentations on investigational stemness inhibitors napabucasin and amcasertib in nine different advanced tumor types. These tumor types include:
This 4-day conference featured renowned thought leaders and information about cutting-edge research, with addresses by Keynote Speakers and presentations from researchers and clinicians from more than 25 institutions around the world.
Find out more about hallmarks of CSCs, including stemness and aberrant signaling pathways, their resistance to traditional therapies, and their roles in recurrence and metastasis.